

Use of biologics to treat IBD in U.S. adults may be suboptimal

March 29 2019



(HealthDay)—Varied study design and methodology make it difficult to

assess real-world trends in adherence and persistence in use of biologics among U.S. adults with inflammatory bowel disease (IBD), according to a review published online March 14 in the *Journal of Clinical Pharmacy and Therapeutics*.

Shahnaz Khan, M.P.H., from RTI Health Solutions in Research Triangle Park, North Carolina, and colleagues conducted a systematic literature review to assess rates of [adherence](#), [persistence](#), switching, and dose escalations with biologics used to treat IBD in the United States.

The researchers found that the 41 included studies (published from 2012 to 2017) varied greatly in methodology, data sources, population studied, follow-up time, and end point definitions, thus preventing meaningful comparisons across studies. For the studies using a medication possession rate threshold of

Citation: Use of biologics to treat IBD in U.S. adults may be suboptimal (2019, March 29) retrieved 23 April 2024 from

<https://medicalxpress.com/news/2019-03-biologics-ibd-adults-suboptimal.html>

<p>This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.</p>
--